Megan Blanche Murray, M.D., Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 81 | 2024 | 2029 | 8.700 |
Why?
|
| Mycobacterium tuberculosis | 85 | 2024 | 1930 | 8.100 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 49 | 2024 | 944 | 6.290 |
Why?
|
| Tuberculosis, Pulmonary | 31 | 2024 | 843 | 5.800 |
Why?
|
| Antitubercular Agents | 52 | 2024 | 1397 | 5.640 |
Why?
|
| Peru | 46 | 2024 | 891 | 3.170 |
Why?
|
| Isoniazid | 15 | 2024 | 288 | 2.690 |
Why?
|
| Contact Tracing | 13 | 2024 | 275 | 2.410 |
Why?
|
| Family Characteristics | 17 | 2024 | 1004 | 2.400 |
Why?
|
| Sputum | 14 | 2024 | 517 | 2.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 13 | 2019 | 591 | 1.600 |
Why?
|
| Genome, Bacterial | 10 | 2024 | 796 | 1.500 |
Why?
|
| Latent Tuberculosis | 6 | 2024 | 224 | 1.390 |
Why?
|
| Vitamin A Deficiency | 2 | 2022 | 88 | 1.370 |
Why?
|
| Drug Resistance, Bacterial | 12 | 2019 | 1063 | 1.360 |
Why?
|
| Rifampin | 14 | 2024 | 351 | 1.220 |
Why?
|
| Fluoroquinolones | 4 | 2017 | 309 | 1.180 |
Why?
|
| Hemorrhagic Fever, Ebola | 6 | 2016 | 424 | 1.080 |
Why?
|
| Disease Outbreaks | 13 | 2016 | 1761 | 0.960 |
Why?
|
| Microbial Sensitivity Tests | 19 | 2023 | 1967 | 0.850 |
Why?
|
| Ebolavirus | 5 | 2016 | 250 | 0.850 |
Why?
|
| Rain | 3 | 2017 | 60 | 0.820 |
Why?
|
| Pyrazinamide | 5 | 2018 | 60 | 0.800 |
Why?
|
| Diabetes Complications | 8 | 2012 | 1320 | 0.770 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 5 | 2024 | 86 | 0.760 |
Why?
|
| Vitamin D Deficiency | 2 | 2022 | 1388 | 0.760 |
Why?
|
| Models, Theoretical | 12 | 2024 | 3580 | 0.750 |
Why?
|
| Communicable Diseases | 4 | 2024 | 873 | 0.730 |
Why?
|
| Molecular Epidemiology | 7 | 2015 | 473 | 0.720 |
Why?
|
| Disease Transmission, Infectious | 5 | 2021 | 560 | 0.700 |
Why?
|
| Rifabutin | 1 | 2019 | 59 | 0.650 |
Why?
|
| Yaws | 1 | 2018 | 3 | 0.640 |
Why?
|
| Mass Screening | 9 | 2024 | 5457 | 0.620 |
Why?
|
| Humans | 204 | 2024 | 768970 | 0.600 |
Why?
|
| Ethambutol | 3 | 2018 | 59 | 0.600 |
Why?
|
| Vitamin E Deficiency | 1 | 2018 | 30 | 0.600 |
Why?
|
| Infectious Disease Incubation Period | 2 | 2015 | 16 | 0.590 |
Why?
|
| Cluster Analysis | 9 | 2021 | 2732 | 0.590 |
Why?
|
| DNA Gyrase | 2 | 2016 | 86 | 0.580 |
Why?
|
| International Cooperation | 4 | 2020 | 1436 | 0.580 |
Why?
|
| Radiography, Thoracic | 1 | 2024 | 1321 | 0.570 |
Why?
|
| Incidence | 23 | 2020 | 21547 | 0.570 |
Why?
|
| Drug Resistance, Microbial | 4 | 2016 | 830 | 0.550 |
Why?
|
| Income | 5 | 2023 | 1879 | 0.550 |
Why?
|
| Ebola Vaccines | 1 | 2016 | 25 | 0.540 |
Why?
|
| Adolescent | 54 | 2024 | 89244 | 0.530 |
Why?
|
| West Nile Fever | 2 | 2006 | 77 | 0.510 |
Why?
|
| Amidohydrolases | 1 | 2016 | 160 | 0.510 |
Why?
|
| Health Services | 2 | 2017 | 755 | 0.500 |
Why?
|
| Risk Factors | 40 | 2024 | 74976 | 0.500 |
Why?
|
| Poverty | 5 | 2015 | 2720 | 0.500 |
Why?
|
| Selection, Genetic | 3 | 2020 | 878 | 0.490 |
Why?
|
| Adult | 79 | 2024 | 223851 | 0.490 |
Why?
|
| Molecular Typing | 2 | 2017 | 115 | 0.490 |
Why?
|
| Mutation | 21 | 2024 | 30266 | 0.480 |
Why?
|
| Models, Biological | 8 | 2012 | 9499 | 0.470 |
Why?
|
| Child, Preschool | 34 | 2024 | 42683 | 0.460 |
Why?
|
| Entamoebiasis | 1 | 2013 | 12 | 0.460 |
Why?
|
| Protozoan Infections | 1 | 2013 | 38 | 0.450 |
Why?
|
| Young Adult | 43 | 2024 | 60131 | 0.450 |
Why?
|
| Amebiasis | 1 | 2013 | 33 | 0.450 |
Why?
|
| Giardiasis | 1 | 2013 | 28 | 0.450 |
Why?
|
| Blastocystis Infections | 1 | 2013 | 17 | 0.450 |
Why?
|
| Social Class | 1 | 2023 | 2009 | 0.450 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 941 | 0.440 |
Why?
|
| Infant | 28 | 2024 | 36556 | 0.440 |
Why?
|
| Rwanda | 10 | 2024 | 673 | 0.440 |
Why?
|
| HIV Infections | 18 | 2020 | 17591 | 0.430 |
Why?
|
| Socioeconomic Factors | 12 | 2021 | 7861 | 0.430 |
Why?
|
| Child | 40 | 2024 | 80960 | 0.430 |
Why?
|
| DNA, Bacterial | 8 | 2020 | 1478 | 0.430 |
Why?
|
| Male | 88 | 2024 | 365203 | 0.430 |
Why?
|
| Vitamin E | 1 | 2018 | 874 | 0.430 |
Why?
|
| Models, Statistical | 7 | 2016 | 5110 | 0.430 |
Why?
|
| Occupational Diseases | 1 | 2021 | 1458 | 0.420 |
Why?
|
| Primary Prevention | 1 | 2020 | 1187 | 0.420 |
Why?
|
| Qualitative Research | 2 | 2024 | 3143 | 0.420 |
Why?
|
| Antigens, CD1 | 3 | 2021 | 434 | 0.420 |
Why?
|
| Host-Pathogen Interactions | 4 | 2024 | 1469 | 0.420 |
Why?
|
| Female | 90 | 2024 | 397515 | 0.410 |
Why?
|
| Emigration and Immigration | 3 | 2005 | 407 | 0.400 |
Why?
|
| Cation Transport Proteins | 2 | 2012 | 326 | 0.400 |
Why?
|
| Patient Preference | 1 | 2020 | 947 | 0.400 |
Why?
|
| Middle Aged | 60 | 2024 | 223737 | 0.390 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 620 | 0.380 |
Why?
|
| Nutritional Status | 2 | 2016 | 1627 | 0.370 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2011 | 664 | 0.360 |
Why?
|
| Virus Latency | 2 | 2015 | 360 | 0.360 |
Why?
|
| Mining | 1 | 2011 | 93 | 0.350 |
Why?
|
| Age Factors | 13 | 2021 | 18435 | 0.340 |
Why?
|
| India | 5 | 2015 | 2334 | 0.340 |
Why?
|
| BCG Vaccine | 4 | 2018 | 383 | 0.320 |
Why?
|
| Prevalence | 20 | 2024 | 15879 | 0.320 |
Why?
|
| Public Health | 4 | 2021 | 2680 | 0.320 |
Why?
|
| Prospective Studies | 22 | 2024 | 54962 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 5 | 2016 | 7478 | 0.310 |
Why?
|
| Epidemiologic Methods | 3 | 2014 | 1328 | 0.310 |
Why?
|
| Crime Victims | 1 | 2013 | 347 | 0.310 |
Why?
|
| Disease Progression | 8 | 2022 | 13674 | 0.310 |
Why?
|
| Tuberculosis Vaccines | 1 | 2008 | 48 | 0.310 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 14794 | 0.310 |
Why?
|
| South Africa | 10 | 2018 | 1872 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 3 | 2017 | 2714 | 0.300 |
Why?
|
| Ukraine | 2 | 2020 | 151 | 0.300 |
Why?
|
| United Nations | 1 | 2008 | 151 | 0.290 |
Why?
|
| Opportunistic Infections | 1 | 2010 | 375 | 0.290 |
Why?
|
| Survival Analysis | 4 | 2020 | 10115 | 0.290 |
Why?
|
| Vitamin A | 2 | 2022 | 611 | 0.280 |
Why?
|
| Diabetes Mellitus | 5 | 2012 | 5892 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 7 | 2017 | 4785 | 0.280 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 472 | 0.280 |
Why?
|
| Infant, Newborn | 16 | 2024 | 26428 | 0.280 |
Why?
|
| Gold | 1 | 2011 | 488 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 16053 | 0.270 |
Why?
|
| Population Surveillance | 4 | 2011 | 2597 | 0.270 |
Why?
|
| Taiwan | 3 | 2013 | 524 | 0.260 |
Why?
|
| Child Mortality | 3 | 2018 | 204 | 0.260 |
Why?
|
| Cohort Studies | 19 | 2024 | 41808 | 0.260 |
Why?
|
| West Nile virus | 1 | 2006 | 77 | 0.260 |
Why?
|
| Biodiversity | 1 | 2008 | 345 | 0.260 |
Why?
|
| Smoking | 5 | 2021 | 9094 | 0.250 |
Why?
|
| Vitamin D | 1 | 2019 | 3311 | 0.250 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2013 | 828 | 0.250 |
Why?
|
| Environment | 1 | 2011 | 1122 | 0.240 |
Why?
|
| Madagascar | 6 | 2021 | 111 | 0.240 |
Why?
|
| Quantitative Trait Loci | 2 | 2024 | 2133 | 0.240 |
Why?
|
| Air Pollution, Indoor | 3 | 2008 | 931 | 0.240 |
Why?
|
| Maternal Health Services | 2 | 2020 | 472 | 0.230 |
Why?
|
| Logistic Models | 7 | 2023 | 13318 | 0.230 |
Why?
|
| Body Mass Index | 4 | 2017 | 13055 | 0.230 |
Why?
|
| Antibiotics, Antitubercular | 4 | 2013 | 99 | 0.230 |
Why?
|
| Quality of Health Care | 3 | 2019 | 4339 | 0.230 |
Why?
|
| Sierra Leone | 4 | 2016 | 171 | 0.230 |
Why?
|
| Bivalvia | 1 | 2023 | 55 | 0.220 |
Why?
|
| Guinea Pigs | 2 | 2022 | 1309 | 0.220 |
Why?
|
| Lost to Follow-Up | 1 | 2024 | 123 | 0.220 |
Why?
|
| Case-Control Studies | 9 | 2021 | 22296 | 0.220 |
Why?
|
| National Health Programs | 2 | 2020 | 442 | 0.220 |
Why?
|
| Health Facilities | 2 | 2020 | 577 | 0.220 |
Why?
|
| Health Status Disparities | 1 | 2015 | 1886 | 0.210 |
Why?
|
| Tuberculin | 1 | 2022 | 64 | 0.210 |
Why?
|
| Alleles | 2 | 2013 | 6901 | 0.210 |
Why?
|
| Tuberculin Test | 2 | 2022 | 205 | 0.200 |
Why?
|
| Treatment Outcome | 17 | 2024 | 65480 | 0.200 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 8055 | 0.200 |
Why?
|
| Seasons | 3 | 2017 | 1524 | 0.200 |
Why?
|
| Evolution, Molecular | 3 | 2013 | 1894 | 0.200 |
Why?
|
| Genes, Bacterial | 4 | 2017 | 1076 | 0.200 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 136 | 0.200 |
Why?
|
| Rural Population | 7 | 2020 | 2325 | 0.200 |
Why?
|
| Indonesia | 4 | 2024 | 131 | 0.190 |
Why?
|
| Databases, Genetic | 1 | 2009 | 1758 | 0.190 |
Why?
|
| Bacterial Proteins | 7 | 2019 | 3840 | 0.190 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 10276 | 0.190 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 26395 | 0.190 |
Why?
|
| Odds Ratio | 6 | 2022 | 9684 | 0.180 |
Why?
|
| Communicable Disease Control | 3 | 2021 | 857 | 0.180 |
Why?
|
| Anti-HIV Agents | 3 | 2012 | 4576 | 0.180 |
Why?
|
| Epidemics | 3 | 2020 | 517 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2014 | 2598 | 0.180 |
Why?
|
| Shoes | 1 | 2021 | 92 | 0.180 |
Why?
|
| Public Health Practice | 1 | 2003 | 221 | 0.180 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2021 | 113 | 0.180 |
Why?
|
| Aged | 29 | 2024 | 171786 | 0.180 |
Why?
|
| Trehalose | 1 | 2021 | 88 | 0.180 |
Why?
|
| Esters | 1 | 2021 | 212 | 0.180 |
Why?
|
| Lipids | 5 | 2021 | 3345 | 0.180 |
Why?
|
| Treatment Failure | 4 | 2017 | 2664 | 0.170 |
Why?
|
| Sulfhydryl Compounds | 1 | 2021 | 296 | 0.170 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2013 | 148 | 0.170 |
Why?
|
| Probability | 4 | 2011 | 2483 | 0.170 |
Why?
|
| Glycerol Kinase | 1 | 2019 | 15 | 0.170 |
Why?
|
| Measles Vaccine | 1 | 2000 | 80 | 0.170 |
Why?
|
| Genotype | 12 | 2020 | 13048 | 0.170 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 12095 | 0.170 |
Why?
|
| Time Factors | 14 | 2015 | 40261 | 0.170 |
Why?
|
| Developing Countries | 6 | 2021 | 2911 | 0.160 |
Why?
|
| World Health Organization | 2 | 2020 | 1328 | 0.160 |
Why?
|
| Glycoproteins | 2 | 2018 | 2202 | 0.160 |
Why?
|
| Antacids | 1 | 2019 | 94 | 0.160 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 12562 | 0.160 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 205 | 0.160 |
Why?
|
| Papua New Guinea | 1 | 2018 | 47 | 0.160 |
Why?
|
| Antigens, CD1d | 1 | 2019 | 225 | 0.160 |
Why?
|
| Amides | 1 | 2021 | 452 | 0.160 |
Why?
|
| Sex Factors | 5 | 2021 | 10633 | 0.160 |
Why?
|
| Altruism | 1 | 2020 | 212 | 0.160 |
Why?
|
| Health Surveys | 5 | 2017 | 4055 | 0.150 |
Why?
|
| Focus Groups | 1 | 2024 | 1462 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 18068 | 0.150 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 1560 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2022 | 2574 | 0.150 |
Why?
|
| Phagosomes | 1 | 2019 | 198 | 0.150 |
Why?
|
| Bacterial Typing Techniques | 2 | 2012 | 263 | 0.150 |
Why?
|
| Sensitivity and Specificity | 9 | 2020 | 14752 | 0.150 |
Why?
|
| Risk Assessment | 6 | 2020 | 24333 | 0.150 |
Why?
|
| Measles | 1 | 2000 | 181 | 0.150 |
Why?
|
| Capacity Building | 1 | 2020 | 265 | 0.150 |
Why?
|
| DNA Fingerprinting | 3 | 2002 | 114 | 0.150 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 437 | 0.150 |
Why?
|
| Macrophages | 4 | 2024 | 5801 | 0.150 |
Why?
|
| Rural Health Services | 2 | 2019 | 394 | 0.150 |
Why?
|
| Geologic Sediments | 1 | 2018 | 81 | 0.150 |
Why?
|
| Automation | 1 | 2020 | 589 | 0.140 |
Why?
|
| Cough | 1 | 2021 | 598 | 0.140 |
Why?
|
| Pulmonary Medicine | 1 | 2019 | 223 | 0.140 |
Why?
|
| Registries | 1 | 2013 | 8384 | 0.140 |
Why?
|
| Cholera | 2 | 2015 | 754 | 0.140 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 930 | 0.140 |
Why?
|
| Toilet Facilities | 1 | 2016 | 26 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2020 | 6236 | 0.130 |
Why?
|
| Linkage Disequilibrium | 1 | 2021 | 2000 | 0.130 |
Why?
|
| Fees and Charges | 1 | 2017 | 191 | 0.130 |
Why?
|
| Medication Adherence | 3 | 2014 | 2192 | 0.130 |
Why?
|
| HIV | 3 | 2015 | 1597 | 0.130 |
Why?
|
| Health Policy | 4 | 2024 | 2700 | 0.130 |
Why?
|
| Nucleoproteins | 1 | 2016 | 110 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 812 | 0.130 |
Why?
|
| Demography | 2 | 2017 | 1642 | 0.130 |
Why?
|
| Phylogeny | 5 | 2016 | 2843 | 0.130 |
Why?
|
| Mycolic Acids | 2 | 2020 | 54 | 0.130 |
Why?
|
| Data Collection | 4 | 2018 | 3324 | 0.120 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 446 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 12253 | 0.120 |
Why?
|
| Educational Status | 1 | 2023 | 2515 | 0.120 |
Why?
|
| Pandemics | 5 | 2024 | 8749 | 0.120 |
Why?
|
| Diarrhea | 3 | 2017 | 1320 | 0.120 |
Why?
|
| Feces | 2 | 2019 | 1510 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 3438 | 0.120 |
Why?
|
| Th17 Cells | 1 | 2021 | 791 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2014 | 1903 | 0.120 |
Why?
|
| Ofloxacin | 2 | 2011 | 66 | 0.120 |
Why?
|
| Child Development | 3 | 2018 | 2336 | 0.120 |
Why?
|
| Radiography | 2 | 2022 | 6991 | 0.120 |
Why?
|
| Entamoeba | 1 | 2013 | 5 | 0.120 |
Why?
|
| Endolimax | 1 | 2013 | 6 | 0.120 |
Why?
|
| Blastocystis hominis | 1 | 2013 | 6 | 0.120 |
Why?
|
| Carotenoids | 1 | 2017 | 620 | 0.120 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 59739 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2024 | 2241 | 0.110 |
Why?
|
| Anticholesteremic Agents | 1 | 2021 | 972 | 0.110 |
Why?
|
| Immunologic Memory | 1 | 2021 | 1378 | 0.110 |
Why?
|
| Anti-Retroviral Agents | 2 | 2017 | 1795 | 0.110 |
Why?
|
| Giardia lamblia | 1 | 2013 | 23 | 0.110 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 1407 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 239 | 0.110 |
Why?
|
| Child Health Services | 1 | 2019 | 645 | 0.110 |
Why?
|
| Body Height | 1 | 2020 | 1569 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2018 | 754 | 0.110 |
Why?
|
| Autoantigens | 1 | 2018 | 891 | 0.110 |
Why?
|
| Epidemiologic Research Design | 2 | 2021 | 368 | 0.110 |
Why?
|
| Biological Assay | 1 | 2016 | 628 | 0.110 |
Why?
|
| Retrospective Studies | 14 | 2018 | 81903 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2018 | 708 | 0.110 |
Why?
|
| Economic Development | 1 | 2014 | 72 | 0.110 |
Why?
|
| Cost of Illness | 3 | 2010 | 1960 | 0.110 |
Why?
|
| Point-of-Care Systems | 3 | 2020 | 1240 | 0.110 |
Why?
|
| Cause of Death | 2 | 2018 | 3721 | 0.110 |
Why?
|
| Community Health Planning | 1 | 2013 | 164 | 0.110 |
Why?
|
| Sentinel Surveillance | 2 | 2021 | 292 | 0.100 |
Why?
|
| Genetic Loci | 2 | 2019 | 2630 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2024 | 2748 | 0.100 |
Why?
|
| Metformin | 1 | 2020 | 909 | 0.100 |
Why?
|
| Insurance, Health | 2 | 2017 | 2518 | 0.100 |
Why?
|
| RNA, Viral | 3 | 2016 | 2871 | 0.100 |
Why?
|
| Disease Susceptibility | 3 | 2007 | 1794 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3118 | 0.100 |
Why?
|
| Species Specificity | 2 | 2008 | 2417 | 0.100 |
Why?
|
| Aminoglycosides | 1 | 2013 | 161 | 0.100 |
Why?
|
| Alcohol Drinking | 2 | 2016 | 4045 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3241 | 0.100 |
Why?
|
| Cholera Vaccines | 1 | 2015 | 264 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 4124 | 0.100 |
Why?
|
| Population Dynamics | 1 | 2014 | 314 | 0.100 |
Why?
|
| Overweight | 1 | 2023 | 2448 | 0.100 |
Why?
|
| Urban Population | 2 | 2017 | 2046 | 0.100 |
Why?
|
| 5' Untranslated Regions | 1 | 2013 | 255 | 0.090 |
Why?
|
| Community Networks | 1 | 2013 | 202 | 0.090 |
Why?
|
| Lung | 4 | 2024 | 10099 | 0.090 |
Why?
|
| Mortality | 2 | 2021 | 2914 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2019 | 3860 | 0.090 |
Why?
|
| Forecasting | 2 | 2020 | 2945 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 4592 | 0.090 |
Why?
|
| Catalase | 1 | 2011 | 215 | 0.090 |
Why?
|
| Antigens, Viral | 1 | 2015 | 996 | 0.090 |
Why?
|
| Binding Sites | 1 | 2019 | 6023 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2020 | 2592 | 0.090 |
Why?
|
| Models, Econometric | 2 | 2014 | 215 | 0.090 |
Why?
|
| Gene Duplication | 1 | 2012 | 315 | 0.090 |
Why?
|
| Comorbidity | 4 | 2014 | 10592 | 0.090 |
Why?
|
| Growth Disorders | 1 | 2015 | 635 | 0.090 |
Why?
|
| Genetic Variation | 5 | 2024 | 6611 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2018 | 3463 | 0.090 |
Why?
|
| Empirical Research | 1 | 2010 | 119 | 0.090 |
Why?
|
| Water | 1 | 2016 | 1421 | 0.080 |
Why?
|
| Autoimmunity | 1 | 2018 | 1360 | 0.080 |
Why?
|
| Premature Birth | 1 | 2022 | 1830 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2021 | 2085 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 948 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2018 | 3810 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 5 | 2014 | 5544 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2019 | 1137 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 5801 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2017 | 2508 | 0.080 |
Why?
|
| Basic Reproduction Number | 1 | 2008 | 38 | 0.080 |
Why?
|
| Social Environment | 1 | 2014 | 1015 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6547 | 0.080 |
Why?
|
| Malnutrition | 1 | 2015 | 632 | 0.080 |
Why?
|
| Reproducibility of Results | 7 | 2017 | 20245 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 2190 | 0.080 |
Why?
|
| Biological Evolution | 2 | 2021 | 1077 | 0.080 |
Why?
|
| Vaccination | 2 | 2024 | 3438 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2012 | 753 | 0.070 |
Why?
|
| Computer Simulation | 6 | 2013 | 6291 | 0.070 |
Why?
|
| Feeding Behavior | 2 | 2017 | 3205 | 0.070 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5375 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 3110 | 0.070 |
Why?
|
| Gene Expression | 2 | 2019 | 7603 | 0.070 |
Why?
|
| Research Design | 2 | 2010 | 6214 | 0.070 |
Why?
|
| Interviews as Topic | 3 | 2024 | 2744 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2716 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2635 | 0.070 |
Why?
|
| Infection Control | 3 | 2020 | 985 | 0.070 |
Why?
|
| Survival Rate | 2 | 2015 | 12873 | 0.070 | |